Skip to content

New and Emerging Treatments for Schizophrenia | Dr. Christoph Correll

2025 APA Scientific Conference

Please click "Next" if you did not attend this session
250%
The session met the stated learning objectives:(Required.)
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents;
Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and
Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other.
Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):(Required.)
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
The session was educationally relevant.
The presenter was educationally effective.
The session provided interactive opportunities.
The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice
Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):(Required.)
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
The session and presenter did NOT have commercial or other inappropriate bias.
Please provide any other comments you would like to share: